Exscientia Announces Investment of up to $525M
Exscientia Announces Investment of up to $525M Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia's discretion Financing led by SoftBank Vision Fund 2 Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 i led the Series D and was joined by previous round lead investors, Novo Holdings and funds mana...